Premium
Ertugliflozin: a new SGLT2 inhibitor for type 2 diabetes
Author(s) -
Chaplin Steve
Publication year - 2019
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1798
Subject(s) - medicine , type 2 diabetes , adverse effect , diabetes mellitus , transporter , pharmacology , endocrinology , biochemistry , chemistry , gene
Ertugliflozin (Steglatro) is a new sodiumglucose co‐transporter‐2 (SGLT2) inhibitor for the treatment of adults with type 2 diabetes. This article examines its place in therapy, clinical trial efficacy and adverse effects.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom